A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-α in anemic patients with low-risk MDS-Reference-Cited by-同舟云学术

A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-α in anemic patients with low-risk MDS

Published:2018-03-30 Issue:12 Volume:32 Page:2648-2658
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Fenaux Pierre,Santini Valeria,Spiriti Maria Antonietta Aloe,Giagounidis Aristoteles,Schlag Rudolf,Radinoff Atanas,Gercheva-Kyuchukova Liana,Anagnostopoulos Achilles,Oliva Esther Natalie,Symeonidis Argiris,Berger Mathilde Hunault,Götze Katharina S.,Potamianou Anna,Haralampiev Hari,Wapenaar Robert,Milionis Iordanis,Platzbecker Uwe

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/s41375-018-0118-9.pdf

Reference24 articles.

1. Steensma DP. Are myelodysplastic syndromes ‘cancer’? Unexpected adverse consequences of linguistic ambiguity. Leuk Res. 2006;30:1227–33.

2. Porta MGD, Malcovati L. Clinical relevance of extra-hematologic comorbidity in the management of patients with myelodysplastic syndrome. Haematologica. 2009;94:602–6.

3. Raza A, Reeves JA, Feldman EJ, Dewald GW, Bennett JM, Deeg HJ, et al. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood. 2008;111:86–93.

4. Terpos E, Mougiou A, Kouraklis A, Chatzivassili A, Michalis E, Giannakoulas N, et al. Prolonged administration of erythropoietin increases erythroid response rate in myelodysplastic syndromes: a phase II trial in 281 patients. Br J Haematol. 2002;118:174–80.

5. Giagounidis A, Mufti GJ, Mittelman M, Sanz G, Platzbecker U, Muus P, et al. Outcomes in RBC transfusion-dependent patients with low-/intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study. Eur J Haematol. 2014;93:429–38.

Cited by 114 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A stimulating advance in erythropoiesis for patients with myelodysplastic syndromes;The Lancet Haematology;2024-09

2. Clinical Outcomes and Healthcare Resource Utilization for Patients With Lower-Risk Myelodysplastic Syndromes Treated With Erythropoiesis-Stimulating Agents;Clinical Lymphoma Myeloma and Leukemia;2024-09

3. Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial;The Lancet Haematology;2024-09

4. Beyond HMAs: Novel targets and therapeutic approaches;Seminars in Hematology;2024-08

5. Infections and antimicrobial prophylaxis in patients with myelodysplastic syndromes;Seminars in Hematology;2024-08